ARTICLE | Company News
Genesis Biopharma, SciMeDent Health Corp. deal
July 5, 2010 7:00 AM UTC
The companies signed a binding letter of intent under which Genesis will grant SciMeDent (formerly Trend Exploration Inc.) exclusive, worldwide rights to R-954 to treat painful diabetic neuropathy. Ge...